Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1657, 2008-01, pp. : 14-14
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
KRAS status predicts response to cetuximab in mCRC
Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. :
Cetuximab launched for mCRC, approved for SCCHN.
Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. :
Cetuximab first line in mCRC: benefits CRYSTAL clear
Inpharma, Vol. 1, Iss. 1593, 2007-01 ,pp. :
Cetuximab improves HRQOL in patients with CRC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 574, 2009-01 ,pp. :
Bevacizumab gives a boost to chemotherapeutics in mCRC
Inpharma, Vol. 1, Iss. 1603, 2007-01 ,pp. :